Statin Therapy in Heart Failure: Potential Mechanisms of Benefit

Heart Failure, Congestive Clinical Trial

Official title:

A Double-blind Randomized, Placebo-Controlled, Single-Center Study to Assess the Impact of Statins on the Autonomic Nervous System and Cardiac Structure/Function in Non-Ischemic Heart Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00233480
• Other study ID #: UCLA IRB #04-12-007-01
• Secondary ID: 1K23HL085097-01A
• Status: Completed
• Phase: Phase 4
• Start date: August 2005
• Est. completion date: February 2009

Study information

• Verified date: March 2020
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of the investigators' study is to further understand the potentially beneficial effects of statin therapy in patients with heart failure. It is hypothesized that statins will 1) increase the heart's pumping ability 2) improve functioning of the sympathetic nervous system and 3) decrease immune activation in heart failure.

Description:

Recent evidence suggests that HMG-Coenzyme A (statin) therapy may be associated with improved survival in both ischemic and non-ischemic heart failure (HF). Large, randomized outcome studies of statins in HF are currently underway, but these trials will not address underlying mechanisms. The aim of the study is to investigate statins' potentially beneficial mechanisms of action in HF, focusing on: 1) sympathetic nervous system activation and 2) myocardial remodeling, and 3) immune activation in heart failure.

Fifty patients with systolic HF of non-ischemic etiology from a single center will be randomized in a double-blinded fashion to 3 months of atorvastatin 10mg QD (25 subjects) vs matching placebo QD (25 subjects). The following exams will be performed at baseline (pre-treatment) and at end of study (post-treatment): sympathetic microneurography, echocardiography, and peripheral blood chemokine analysis. Sympathetic microneurography at the peroneal nerve will directly quantify changes in sympathetic nerve activity (bursts/minute). Echocardiography (with the addition of MRI in a subset of subjects without pacemakers or implantable defibrillators) will be used to track changes in cardiac structure and function; indices of remodeling will include measurement of left ventricular mass index, left ventricular volume indices, left ventricular ejection fraction, and subendocardial scar quantification (MRI only). Immune activation will be characterized by circulating cytokines and chemokines. Additionally, quantification of established cardiac biomarkers (cardiac troponin, B-type natriuretic peptide, and C-reactive Protein), Holter monitor/heart rate variability studies, and quality of life and global clinical assessment will be performed pre- and post- treatment.

Neither sympathetic microneurography nor MRI have been previously utilized to assess statins' effects in humans with HF. The impact of statin therapy on inflammatory chemokine activation in HF also has not been studied. The knowledge gained from our proposed investigations may serve as a basis for understanding how statin therapy has potential to improve clinical outcomes in HF, and may ultimately lead to new therapeutic strategies for HF.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: February 2009
• Est. primary completion date: February 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age=18 years old

• LVEF = 35%, as documented by echocardiography, radionuclide ventriculography, gated SPECT, or contrast ventriculography within past 6 months

• Symptomatic HF (NYHA II-IV) or current NYHA I with history of symptomatic HF within the last year

• Stable doses of optimal HF medical therapy, unless documented contraindication.

Exclusion Criteria:

• Ischemic etiology of HF, defined as the presence of at least one of the following four criteria; angiographic evidence of > 50% lesion in 1 or more of the 3 major epicardial vessels; history of myocardial infarction; history of revascularization procedure; evidence of significant perfusion defect in the setting of ischemic symptoms.

• Clinical indication for statin treatment - coronary artery, cerebrovascular, or peripheral vascular disease

• Major cardiovascular event or surgical procedure within past 8 weeks

• LDL<70 mg/dL

• HF secondary to congenital heart disease or uncorrected valvular disease

• Treatment with statin within past 2 months

• Pregnancy

• Contraindication to statin: moderate liver disease, AST/ALT > 150 U/ L, known hypersensitivity

• Likely to receive heart transplant within 3 months

• Known peripheral or autonomic neuropathy

Related Conditions & MeSH terms

• Heart Failure
• Heart Failure, Congestive

Intervention

Drug:
• atorvastatin
atorvastatin 10mg PO QD
• placebo
matched placebo Qd x 3 months

Locations

Country	Name	City	State
United States	Ahmanson-UCLA Cardiomyopathy Center	Los Angeles	California

Sponsors (3)

Lead Sponsor	Collaborator
University of California, Los Angeles	National Heart, Lung, and Blood Institute (NHLBI), Pfizer

Country where clinical trial is conducted

United States, 

References & Publications (3)

Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007 Dec;8(17):3061-8. Review. — View Citation

Horwich TB, Middlekauff HR. Potential autonomic nervous system effects of statins in heart failure. Heart Fail Clin. 2008 Apr;4(2):163-70. doi: 10.1016/j.hfc.2008.01.004. — View Citation

PubMed ID 22041323

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	LVEF (Left Ventricular Ejection Fraction)	Left ventricular ejection fraction was assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks).	baseline and three months
Primary	Muscle Sympathetic Nerve Activity (by Sympathetic Microneurography)		Baseline and three months
Secondary	Left Ventricular End-diastolic Dimension (LVEDD)	The end-diastolic dimension of the left ventricle (in mm) was measured with 2D echocardiography performed by experienced technicians using Acuson Sequoia Echocardiography System	Baseline and three months
Secondary	Cardiac Biomarker Level BNP	B-type natriuretic peptide, measured pg/mL at baseline and post-treatment	Baseline, 3 months
Secondary	High-sensitivity C-reactive Protein (hsCRP) as a Cardiac Biomarker		Baseline, Three months
Secondary	Cardiac Troponin I (cTnI)	Participants with cTnI =0.04 ng/mL	Baseline, Three months